Final Overall Survival Results from the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)
Published Online: Lorusso D, Gladieff L, O’Malley DM, et al. The Lancet, 10 April 2026, DOI: 10.1016/S0140-6736(26)00462-9
Presented: Society of Gynecologic Oncology, 10 April 2026, San Juan, Puerto Rico
Presenter: Alexander B Olawaiye, M.D.
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.